FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981034056> ?p ?o ?g. }

• W1981034056 abstract "You have accessJournal of UrologyProstate Cancer: Advanced II1 Apr 2010671 HORMON RESISTANT PROSTATE CANCER TREATED BY ROBOTIC HIGH INTENSIVE ULTRASOUND Christian Chaussy, Stefan Thueroff, and Regina Nanieva Christian ChaussyChristian Chaussy More articles by this author , Stefan ThueroffStefan Thueroff More articles by this author , and Regina NanievaRegina Nanieva More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1058AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Hormonal resistant prostate cancer (HRPCa) is an increasing problem in prostate cancer therapy, because of longer patient survival under hormonal ablation. We analyze how local tumor ablation by robotic high intensity focused ultrasound (rHIFU) influences disease progression and whether this local therapy shows differences in efficacy treating local and systemic disease. METHODS 55 patients with PSA progression under definitive hormonal ablation (HA) with local biopsy proven tumor and a minimum follow up of 1 year after rHIFU for local HRPC therapy. HRPC was defined as tripple PSA increase under long term (> 2 years) hormonal ablation. rHIFU was performed in one session in spinal anesthesia, accompanied by TUR and performed completly at 3 MHz by Ablatherm® (EDAP-TMS, Lyon). Efficacy and side effect profile is analyzed in a max. follow up of 9.5 years. RESULTS Inclusions: age 76(62-88); Staging: T2: 20%, T3-4: 80%; N+: 15%, M+: 11%; Gleason: 7.5(4-9); HA duration (months): 48(4-137); PSAtr (at HIFU therapy): 8ng/ml (0.9-491; 57% <10ng/ml, 16% >20ng/ml). Efficacy: PSA Nadir: 1.8ng/ml (0-148): this integrates 37% <4ng/ml and 28% >20mg/ml. time to Nadir (months): 1.7(0.2-8.5). PSA reduction: 80% (N0/M0), 65% (N+/M+). Follow up time (months): 21(6.6-114), Last PSA: 7.9 ng/ml (0-320); Deaths within follow up: PCa related: 7, not PCa related: 5; unknown reason: 10. Alive: 23/55 (40%) HRPC patients after median 21 months. Side effects (HIFU related postoperative acc. Clavien (1-5)): 15% (Clavien 1-3 in 8/55 cases only). Any adverse events in follow up: 23.6% (50% local obstructive reasons). CONCLUSIONS Local adjuvant tumor ablation by “TUR & rHIFU” reduces PSA by 80% in local disease and 65% in systemic disease. This new minimal invasive, single session, adjuvant concept in treatment of HRPC showed its high efficacy as additional therapy in prostate cancer therapy in an most unfavourable patient group. 40% of the patients were still living after a follow up of 23 months with a PSA below entryPSA at treatment inclusion. Adjuvant local tumor ablation by rHIFU achieved a longer survival in good life quality. It was accompanied by a low and moderate side effect rate. It substituted or preserved more invasive or systemic therapies as salvage prostatectomy or chemotherapy for later use. Muenchen, Germany© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e262 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian Chaussy More articles by this author Stefan Thueroff More articles by this author Regina Nanieva More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W1981034056 created "2016-06-24" @default.
• W1981034056 creator A5038417262 @default.
• W1981034056 creator A5079056072 @default.
• W1981034056 creator A5079937317 @default.
• W1981034056 date "2010-04-01" @default.
• W1981034056 modified "2023-09-25" @default.
• W1981034056 title "671 HORMON RESISTANT PROSTATE CANCER TREATED BY ROBOTIC HIGH INTENSIVE ULTRASOUND" @default.
• W1981034056 doi "https://doi.org/10.1016/j.juro.2010.02.1058" @default.
• W1981034056 hasPublicationYear "2010" @default.
• W1981034056 type Work @default.
• W1981034056 sameAs 1981034056 @default.
• W1981034056 citedByCount "3" @default.
• W1981034056 countsByYear W19810340562012 @default.
• W1981034056 countsByYear W19810340562017 @default.
• W1981034056 crossrefType "journal-article" @default.
• W1981034056 hasAuthorship W1981034056A5038417262 @default.
• W1981034056 hasAuthorship W1981034056A5079056072 @default.
• W1981034056 hasAuthorship W1981034056A5079937317 @default.
• W1981034056 hasConcept C121608353 @default.
• W1981034056 hasConcept C126322002 @default.
• W1981034056 hasConcept C126838900 @default.
• W1981034056 hasConcept C126894567 @default.
• W1981034056 hasConcept C141071460 @default.
• W1981034056 hasConcept C143753070 @default.
• W1981034056 hasConcept C2776235491 @default.
• W1981034056 hasConcept C2777365067 @default.
• W1981034056 hasConcept C2778311097 @default.
• W1981034056 hasConcept C2778902805 @default.
• W1981034056 hasConcept C2780192828 @default.
• W1981034056 hasConcept C509974204 @default.
• W1981034056 hasConcept C71924100 @default.
• W1981034056 hasConceptScore W1981034056C121608353 @default.
• W1981034056 hasConceptScore W1981034056C126322002 @default.
• W1981034056 hasConceptScore W1981034056C126838900 @default.
• W1981034056 hasConceptScore W1981034056C126894567 @default.
• W1981034056 hasConceptScore W1981034056C141071460 @default.
• W1981034056 hasConceptScore W1981034056C143753070 @default.
• W1981034056 hasConceptScore W1981034056C2776235491 @default.
• W1981034056 hasConceptScore W1981034056C2777365067 @default.
• W1981034056 hasConceptScore W1981034056C2778311097 @default.
• W1981034056 hasConceptScore W1981034056C2778902805 @default.
• W1981034056 hasConceptScore W1981034056C2780192828 @default.
• W1981034056 hasConceptScore W1981034056C509974204 @default.
• W1981034056 hasConceptScore W1981034056C71924100 @default.
• W1981034056 hasIssue "4S" @default.
• W1981034056 hasLocation W19810340561 @default.
• W1981034056 hasOpenAccess W1981034056 @default.
• W1981034056 hasPrimaryLocation W19810340561 @default.
• W1981034056 hasRelatedWork W1523455587 @default.
• W1981034056 hasRelatedWork W2023913024 @default.
• W1981034056 hasRelatedWork W2026414220 @default.
• W1981034056 hasRelatedWork W2127440557 @default.
• W1981034056 hasRelatedWork W2336442715 @default.
• W1981034056 hasRelatedWork W2374039895 @default.
• W1981034056 hasRelatedWork W2885733447 @default.
• W1981034056 hasRelatedWork W3004337829 @default.
• W1981034056 hasRelatedWork W3029905168 @default.
• W1981034056 hasRelatedWork W83392053 @default.
• W1981034056 hasVolume "183" @default.
• W1981034056 isParatext "false" @default.
• W1981034056 isRetracted "false" @default.
• W1981034056 magId "1981034056" @default.
• W1981034056 workType "article" @default.